What Is ICD-10 Code Z12.11?
ICD-10 code Z12.11 is the diagnosis code for an encounter for screening for malignant neoplasm of the colon, used when an asymptomatic patient undergoes a screening colonoscopy or other colorectal cancer screening procedure. It is the primary diagnosis code on every screening colonoscopy claim and is what tells the payer the procedure was preventive rather than diagnostic, which directly determines whether the patient owes cost-sharing under ACA preventive care rules.
When to use it: Z12.11 is the first-listed diagnosis for any screening colonoscopy on an asymptomatic patient with no signs or symptoms of colorectal disease. It pairs with G0121 (average risk, Medicare) or G0105 (high risk, Medicare), or with CPT 45378 and modifier 33 for commercial payers.
Screening vs diagnostic: If the patient has symptoms such as rectal bleeding, abdominal pain, or a change in bowel habits, the encounter is diagnostic, not screening. Use the symptom or condition code as the primary diagnosis instead of Z12.11.
When a polyp is found: Z12.11 remains the primary diagnosis even when a polyp is discovered and removed during a screening colonoscopy. The finding does not retroactively change the intent of the encounter from screening to diagnostic.
What Z12.11 Covers
Z12.11 falls under ICD-10-CM category Z12, which captures encounters for screening for malignant neoplasms. The full descriptor is “Encounter for screening for malignant neoplasm of colon.” It is a billable, specific code that does not require additional characters, and it is exempt from present-on-admission (POA) reporting.
The code applies to the entire range of colorectal cancer screening methods: screening colonoscopy, fecal immunochemical test (FIT), fecal occult blood test (FOBT or gFOBT), stool DNA test (Cologuard), CT colonography, and flexible sigmoidoscopy when performed as a cancer screening rather than a diagnostic workup. In gastroenterology practice, the most common pairing is Z12.11 with a screening colonoscopy procedure code.
One question we hear constantly from GI practice managers is whether Z12.11 applies to surveillance colonoscopies in patients with a history of polyps. The answer is yes. A surveillance colonoscopy is still a screening exam. The patient is being screened for malignancy, and Z12.11 is the correct primary diagnosis. The personal history code, Z86.010 (personal history of colonic polyps) or Z86.0101 (personal history of adenomatous and serrated colon polyps, effective October 1, 2024), is reported as a secondary diagnosis to explain why the screening interval is shorter than standard.
How to Bill Z12.11 for Medicare Screening Colonoscopies
Medicare billing for screening colonoscopies follows a specific code pairing that depends on the patient’s risk level. The diagnosis code is Z12.11 in both cases, but the procedure code differs.
For average-risk patients, report HCPCS code G0121 (colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk) with Z12.11 as the primary diagnosis. Medicare covers this every 10 years for beneficiaries aged 45 and older, per the USPSTF recommendation that CMS adopted. For high-risk patients, such as those with a family history of colorectal cancer or a personal history of adenomatous polyps, report HCPCS code G0105 (colorectal cancer screening; colonoscopy on individual at high risk) with Z12.11 as primary and the appropriate risk-factor code (Z80.0 for family history of malignant neoplasm of digestive organs, or Z86.010 for personal history of colonic polyps) as secondary. Medicare covers G0105 every two years for high-risk beneficiaries.
Under the Consolidated Appropriations Act of 2021, Medicare waives the Part B deductible and phases down coinsurance for screening colonoscopies even when a polyp is found and removed during the procedure. Before this change, the screening-to-diagnostic conversion triggered a 20% coinsurance obligation for the patient. In 2026 the patient owes 15% coinsurance, dropping to 10% for 2027 through 2029 and 0% in 2030. Getting this right is one of the most important billing details in GI practice, because it eliminates a major source of patient billing disputes. For a breakdown of the diagnostic colonoscopy procedure code itself, see our guide to CPT code 45378.
Z12.11 Code Pairings for Screening Colonoscopy
| Scenario | Primary Dx | Procedure Code | Secondary Dx |
| Average-risk screening (Medicare) | Z12.11 | G0121 | None required |
| High-risk screening, family history (Medicare) | Z12.11 | G0105 | Z80.0 |
| High-risk screening, personal hx of polyps (Medicare) | Z12.11 | G0105 | Z86.010 or Z86.0101 |
| Screening colonoscopy (commercial payer) | Z12.11 | 45378 with modifier 33 | Per payer policy |
| Screening converted to therapeutic (polyp removed) | Z12.11 | 45385 with modifier PT | K63.5 (polyp found) |
| Surveillance after prior polyps (Medicare) | Z12.11 | G0105 | Z86.010 or Z86.0101 |
What Happens When a Screening Colonoscopy Finds a Polyp?
When a screening colonoscopy discovers a polyp and the physician removes it during the same session, the encounter does not change from screening to diagnostic. Z12.11 remains the primary diagnosis. The polyp finding (typically K63.5, polyp of colon, or a more specific benign neoplasm code from the D12 range) is reported as a secondary diagnosis. The procedure code changes from the screening colonoscopy code to the therapeutic code that matches the removal technique, such as CPT 45385 for colonoscopy with snare polypectomy.
This is where modifier PT enters the picture. Modifier PT (colorectal cancer screening test, converted to diagnostic test or other procedure) is appended to the therapeutic procedure code to tell the payer that the encounter started as a screening but converted to a therapeutic procedure when a finding was discovered. For Medicare claims, modifier PT triggers the reduced cost-sharing under the Consolidated Appropriations Act of 2021: the deductible is waived and the patient owes only the phased-down coinsurance (15% in 2026) even though a polyp was removed.
Across the billing companies we vet for GI practices, missing modifier PT on a converted screening colonoscopy is one of the top five denial triggers. The claim either denies outright or processes with full patient cost-sharing applied, which generates a patient billing dispute the practice then has to resolve. The fix is a charge capture rule: any screening colonoscopy that results in a polyp removal automatically gets modifier PT appended to the therapeutic CPT code before the claim is submitted.
Screening colonoscopy billing errors are quiet and repetitive: a missing modifier PT, a Z12.11 used on a diagnostic case, or a G0121 billed when G0105 was correct. Each one is a denial or a patient billing dispute that compounds across your claim volume. A billing partner with GI-specific experience catches these before they cost you. Get matched with vetted GI billing companies, free.
Z12.11 vs Z12.12: Colon vs Rectum Screening
Z12.11 is specific to screening for malignant neoplasm of the colon. Z12.12 covers screening for malignant neoplasm of the rectum. In most clinical practice, a screening colonoscopy evaluates both the colon and the rectum, and Z12.11 is the correct primary diagnosis for the encounter because the colonoscopy is primarily a colon cancer screening procedure. Z12.12 is used when the screening is limited to the rectum, which is uncommon in standard GI practice.
The parent code Z12.10 (encounter for screening for malignant neoplasm of intestinal tract, unspecified) exists but should not be used when the specific site is known. Z12.11 is the specific, billable code, and payers expect specificity. Billing with Z12.10 when Z12.11 is supported by the documentation is a coding error that can trigger a request for additional information or a denial.
Common Z12.11 Billing Mistakes
Providers often come to us after a pattern of screening colonoscopy denials with no single obvious cause. When we look at the claims, the same mistakes repeat:
- Using Z12.11 on a diagnostic encounter. If the patient presented with rectal bleeding, iron deficiency anemia, or a positive FIT, the encounter is diagnostic. Z12.11 does not apply, and using it will either trigger a denial or cause the payer to process the claim incorrectly.
- Omitting modifier PT when a screening converts to therapeutic. The polyp removal code without modifier PT looks like a diagnostic procedure to the payer. The cost-sharing waiver does not apply, and the patient gets a bill they should not have received.
- Billing G0121 for a high-risk patient. A patient with a personal history of adenomatous polyps or a family history of colorectal cancer qualifies for G0105, not G0121. G0121 is for average-risk patients only. Billing the wrong screening code can result in a frequency denial if the patient had a prior colonoscopy within the G0121 10-year interval but is within the G0105 2-year interval.
- Failing to report the secondary risk-factor diagnosis. G0105 requires a secondary code explaining the high-risk status (Z80.0, Z86.010, or Z86.0101). Submitting G0105 with Z12.11 alone and no supporting risk code invites a documentation request or a denial.
- Confusing surveillance with diagnostic follow-up. A surveillance colonoscopy on a patient with a history of polyps is a screening exam (Z12.11 primary). A follow-up colonoscopy six months after a polypectomy to check for recurrence is a follow-up exam (Z09 primary). The codes are different, and using the wrong one changes the coverage determination.
Frequently Asked Questions
What does ICD-10 code Z12.11 mean?
Z12.11 is the ICD-10-CM code for an encounter for screening for malignant neoplasm of the colon. It is the primary diagnosis code used on screening colonoscopy claims for asymptomatic patients and tells the payer the procedure was preventive, which affects cost-sharing and coverage rules.
Is Z12.11 used for surveillance colonoscopies?
Yes. A surveillance colonoscopy in a patient with a history of polyps is still a screening exam. Z12.11 is the primary diagnosis, and the personal history code (Z86.010 or Z86.0101) is reported as a secondary diagnosis to explain the shorter screening interval.
Does Z12.11 change when a polyp is found during screening?
No. Z12.11 remains the primary diagnosis even when a polyp is discovered and removed during the screening colonoscopy. The polyp finding is reported as a secondary diagnosis, and modifier PT is appended to the therapeutic procedure code to indicate the screening converted to a therapeutic procedure.
What is the difference between Z12.11 and Z12.12?
Z12.11 is for screening for malignant neoplasm of the colon. Z12.12 is for screening for malignant neoplasm of the rectum. A standard screening colonoscopy evaluates the entire colon and rectum, and Z12.11 is the correct primary diagnosis for that encounter.
Which CPT or HCPCS code pairs with Z12.11?
For Medicare, Z12.11 pairs with G0121 (average-risk screening colonoscopy) or G0105 (high-risk screening colonoscopy). For commercial payers, Z12.11 pairs with CPT 45378 (diagnostic colonoscopy) with modifier 33 (preventive service). If a polyp is removed, the therapeutic code (such as 45385) replaces the screening code, and modifier PT is appended.
Does the patient owe cost-sharing on a screening colonoscopy billed with Z12.11?
Under the ACA, most commercial plans cover screening colonoscopies without patient cost-sharing when billed with Z12.11. For Medicare, the Consolidated Appropriations Act of 2021 waives the deductible and reduces coinsurance to 15% in 2026 (10% for 2027 through 2029, 0% in 2030) when the screening converts to a therapeutic procedure and a polyp is removed, provided modifier PT is on the claim.
Next Steps
For the diagnostic colonoscopy procedure code and its billing requirements, see our guide to CPT code 45378.
When a screening colonoscopy cannot be completed and the scope is withdrawn early, modifier 52 applies. See our breakdown of modifier 52 in medical billing for the documentation and billing rules.
For a look at how GI reimbursement is changing heading into the new year, read the 2027 Medicare GI payment changes overview.
Ready to stop losing revenue on screening colonoscopy claims? Get matched with a billing company that knows GI coding inside and out.
Screening colonoscopy billing touches Z12.11, modifier PT, the G0121/G0105 split, and ACA cost-sharing rules on every claim. One missed modifier or one wrong risk-level code creates a denial that repeats across your entire screening volume. Gastroenterology Billing matches your practice with vetted billing companies that specialize in GI. Over 2,000 providers matched nationwide, rates starting at 2.95%, and the service is 100% free.
